Lisdexamfetamine for binge eating disorder in adults: a systematic review of the efficacy and safety profile for this newly approved indication - what is the number needed to treat, number needed to harm and likelihood to be helped or harmed?

International Journal of Clinical Practice
Leslie Citrome

Abstract

To describe the efficacy and safety of lisdexamfetamine dimesylate (LDX) for the treatment of binge eating disorder (BED). The pivotal registration trials were accessed by querying http://www.ncbi.nlm.nih.gov/pubmed/, http://www.clinicaltrials.gov and http://www.clinicaltrialsregister.eu for the search terms 'lisdexamfetamine' and 'binge', and by also querying the Web of Science (Thomson Reuters) and Embase (Elsevier) commercial databases, and by asking the manufacturer for copies of posters presented at congresses. Product labelling provided additional information. All available clinical reports of studies were identified. Descriptions of the principal results and calculation of number needed to treat (NNT) and number needed to harm (NNH) for relevant dichotomous outcomes were extracted from the available study reports and other sources of information. LDX is a central nervous system stimulant indicated for the treatment of moderate to severe BED. The recommended dose range is 50-70 mg/day. Approval for the treatment of BED was based on a clinical development programme that included an 11-week Phase II proof-of-concept, placebo-controlled study, testing fixed doses of LDX 30, 50 and 70 mg/day, and two 12-week Phase III placebo...Continue Reading

References

Apr 1, 1959·The Psychiatric Quarterly·A J STUNKARD
Jul 4, 2006·Biological Psychiatry·James I HudsonRonald C Kessler
Nov 21, 2007·Current Medical Research and Opinion·Suma M Krishnan, Jeffrey G Stark
May 16, 2008·Acta Psychiatrica Scandinavica·L Citrome
Feb 3, 2009·Obesity·Deborah L Reas, Carlos M Grilo
Nov 22, 2011·The Psychiatric Clinics of North America·G Terence Wilson
Jun 2, 2012·Therapeutics and Clinical Risk Management·Susan L McElroyAnne M O'Melia
Mar 30, 2013·Journal of Psychopharmacology·David J HealDavid J Nutt
Oct 2, 2013·Indian Journal of Psychiatry·Vihang N Vahia
Jan 28, 2014·Expert Opinion on Emerging Drugs·Deborah L Reas, Carlos M Grilo

❮ Previous
Next ❯

Citations

Dec 20, 2015·CNS Spectrums·Leslie Citrome
Mar 8, 2016·Current Treatment Options in Psychiatry·Shauna P Reinblatt
Sep 9, 2015·Current Obesity Reports·Jonathan R S Arch
Jun 10, 2015·Physiology & Behavior·Janet TreasureRobert Turton
Nov 22, 2015·Journal of Psychopharmacology·Steven P VickersDavid J Heal
May 18, 2019·British Journal of Sports Medicine·Claudia L ReardonLars Engebretsen
Apr 17, 2021·Neuropharmacology·Katherine M SerafineEric P Zorrilla
Aug 31, 2021·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Elizabeth SchneiderColin T Dourish
Dec 10, 2021·Current Sports Medicine Reports·Claudia L Reardon

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

© 2022 Meta ULC. All rights reserved